77749-49-6
Chemical Structure
RX-RA-69
- CAS No.: 77749-49-6
- Formula:C21H25N7OS
- Molecular Weight:423.53
InChIKey: LUGKHBNNJJSVLE-UHFFFAOYSA-N
SMILES: C1(N=CN=C2SCC3=CC=CC=C3)=C2N=C(N4CCNCC4)N=C1N5CCOCC5
Biological Activity: RX-RA-69 is an orally active platelet phosphodiesterase (PDE) inhibitor with a IC50 of 1 nM. RX-RA-69 elevates cAMP levels in platelets, exerts anti-aggregatory effects, and inhibits the formation of coronary platelet thrombi. RX-RA-69 exhibits anti-metastatic activity in a mouse Lewis lung cancer model. RX-RA-69 can be used in research related to coronary platelet thrombi and Lewis lung cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RX-RA-69 | RX-RA-69 is an orally active platelet phosphodiesterase (PDE) inhibitor with a IC50 of 1 nM. RX-RA-69 elevates cAMP levels in platelets, exerts anti-aggregatory effects, and inhibits the formation of coronary platelet thrombi. RX-RA-69 exhibits anti-metastatic activity in a mouse Lewis lung cancer model. RX-RA-69 can be used in research related to coronary platelet thrombi and Lewis lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Machleidt C, et al. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69. Thromb Res. 1985;37(5):595-604. [Content Brief]
- [2]. Lichtner R, et al. Antimetastatic action of RX-RA 69, a new potent PDE-inhibitor in the Lewis lung carcinoma of the mouse. Prog Clin Biol Res. 1982;89:131-141. [Content Brief]
Keywords
